Aldo Scarpa

List of Publications by Year in Descending Order

653 papers	44,104 citations	88 h-index	190 g-index
745 ext. papers	51,365 ext. citations	5.9 avg, IF	6.8 L-index

#	Paper	IF	Citations
653	Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants.. *Familial Cancer*, **2022**, 1	3	0
652	Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. **2022**, 10,		3
651	Evidence of glucose absorption in a neoformed intestine.. *Updates in Surgery*, **2022**, 1	2.9	
650	Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series.. *Current Oncology*, **2022**, 29, 178-185	2.8	0
649	Recurrent oligodendroglioma with changed 1p/19q status.. *Neuropathology*, **2022**,	2	0
648	ICGC-ARGO precision medicine: familial matters in pancreatic cancer.. *Lancet Oncology, The*, **2022**, 23, 25-26	21.7	2
647	Surgical treatment of ductal biliary recurrence of poorly cohesive gastric cancer mimicking primary biliary tract cancer: a case report.. *Journal of Surgical Case Reports*, **2022**, 2022, rjac132	0.6	
646	Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol.. *Annals of Surgical Oncology*, **2022**, 1	3.1	1
645	CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2022**, 1	5.1	
644	"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms.. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2022**, 1	5.1	0
643	ASO Visual Abstract: Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective Lymphadenectomy Protocol.. *Annals of Surgical Oncology*, **2022**, 1	3.1	
642	ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer.. *Lancet Oncology, The*, **2022**, 23, 463-464	21.7	0
641	Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature.. *Pathologica*, **2022**, 114, 164-169	1.9	1
640	Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases.. *Endocrine Pathology*, **2022**, 1	4.2	0
639	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. *ESMO Open*, **2022**, 7, 100459	6	1
638	Pathology of Biliary Tract Cancers **2022**, 65-70		
637	Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. *Gut*, **2021**, 70, 319-329	19.2	16

636	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. *Nature Communications*, **2021**, 12, 6738	17.4	1
635	Artificial intelligence in oncology: current applications and future perspectives. *British Journal of Cancer*, **2021**,	8.7	12
634	ROR1 and ROR2 expression in pancreatic cancer. *BMC Cancer*, **2021**, 21, 1199	4.8	0
633	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.. *ESMO Open*, **2021**, 7, 100308	6	2
632	Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. *Nature Communications*, **2021**, 12, 5623	17.4	7
631	Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 1	5.1	3
630	Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. *Journal of Clinical Pathology*, **2021**, 74, 668-672	3.9	1
629	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. *Gut*, **2021**, 70, 1904-1913	19.2	9
628	Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. *Gut*, **2021**, 70, 1768-1781	19.2	7
627	Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different Germline Mutations: New Horizons from Tumor Molecular Profiling. *Genes*, **2021**, 12,	4.2	8
626	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. *European Journal of Cancer*, **2021**, 146, 56-73	7.5	32
625	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
624	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. *Frontiers in Oncology*, **2021**, 11, 650293	5.3	4
623	Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report. *Frontiers in Oncology*, **2021**, 11, 663489	5.3	1
622	Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis. *Diagnostics*, **2021**, 11,	3.8	10
621	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. *Gut*, **2021**,	19.2	15
620	Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome. *Endocrine*, **2021**, 74, 180-187	4	1
619	Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data. *European Journal of Cancer*, **2021**, 148, 348-358	7.5	0

618	Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. *Cancers*, **2021**, 13,	6.6	10
617	Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. *Npj Precision Oncology*, **2021**, 5, 61	9.8	3
616	H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 987-996	5.1	5
615	Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?. *Current Oncology Reports*, **2021**, 23, 106	6.3	2
614	Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. *Annals of Surgery*, **2021**, 274, e134-e142	7.8	17
613	Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. *Annals of Surgery*, **2021**, 274, 1051-1057	7.8	21
612	Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. *Gut*, **2021**, 70, 148-156	19.2	64
611	Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum?. *Journal of Gastrointestinal Surgery*, **2021**, 25, 333-336	3.3	3
610	Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 478, 319-326	5.1	8
609	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. *Gastroenterology*, **2021**, 160, 362-377.e13	13.3	32
608	Epithelial Nr5a2 heterozygosity cooperates with mutant Kras in the development of pancreatic cystic lesions. *Journal of Pathology*, **2021**, 253, 174-185	9.4	3
607	Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 45-51	3.1	1
606	ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. *Annals of Oncology*, **2021**, 32, 337-350	10.3	24
605	The histopathological diagnosis of atypical meningioma: glass slide versus whole slide imaging for grading assessment. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 478, 747-756	5.1	3
604	Molecular Biology of Neuroendocrine Tumors **2021**, 37-53		
603	Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211006947	5.4	1
602	Clinical Significance of Preoperative Inflammatory Markers in Prediction of Prognosis in Node-Negative Colon Cancer: Correlation between Neutrophil-to-Lymphocyte Ratio and Poorly Differentiated Clusters. *Biomedicines*, **2021**, 9,	4.8	3
601	Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?. *Gut*, **2021**, 70, 1809-1811	19.2	6

600	IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	7
599	Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. *Pancreas*, **2021**, 50, 138-146	2.6	1
598	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. *Genome Medicine*, **2021**, 13, 15	14.4	6
597	Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and Homozygous Deletion on Recurrence-Free Survival. *Cancers*, **2021**, 13,	6.6	4
596	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. *Communications Biology*, **2021**, 4, 155	6.7	11
595	Neuroendocrine neoplasms of the biliary tree, liver and pancreas: a pathological approach. *Pathologica*, **2021**, 113, 28-38	1.9	7
594	Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. *Journal of Clinical Oncology*, **2021**, 39, 2617-2631	2.2	15
593	Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival. *Pathology Research and Practice*, **2021**, 224, 153519	3.4	3
592	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. *Pathologica*, **2021**, 113, 262-271	1.9	5
591	Hemodynamics and remodeling of the portal confluence in patients with malignancies of the pancreatic head: a pilot study towards planned and circumferential vein resections. *Langenbeckis Archives of Surgery*, **2021**, 1	3.4	0
590	Molecular Analysis of an Intestinal Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) Reveals MLH1 Methylation-driven Microsatellite Instability and a Monoclonal Origin: Diagnostic and Clinical Implications. *Applied Immunohistochemistry and Molecular Morphology*, **2021**,	1.9	1
589	Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. *Gastroenterology*, **2021**, 161, 899-909.e5	13.3	36
588	Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer **2021**, 9,		4
587	Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. *Gastroenterology*, **2021**,	13.3	1
586	Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. *Cancer Cytopathology*, **2021**,	3.9	4
585	Genomic characterization of hepatoid tumors: context matters. *Human Pathology*, **2021**, 118, 30-41	3.7	1
584	Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. *European Journal of Cancer Prevention*, **2021**, 30, 423-430	2	
583	Diagnostic mesothelioma biomarkers in effusion cytology. *Cancer Cytopathology*, **2021**, 129, 506-516	3.9	4

582	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.. *Acta Neuropathologica Communications*, **2021**, 9, 200	7.3	0
581	Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading.. *Modern Pathology*, **2021**,	9.8	1
580	Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 382	12.8	2
579	Endoscopic ultrasound guided fine needle biopsy samples to drive personalized medicine: A proof of concept study. *Pancreatology*, **2020**, 20, 778-780	3.8	4
578	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. *Cell Reports*, **2020**, 31, 107625	10.6	34
577	Exosomal miRNA signatures of pancreatic lesions. *BMC Gastroenterology*, **2020**, 20, 137	3	12
576	The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells. *Biomolecules*, **2020**, 10,	5.9	4
575	Liver Tumor Burden in Pancreatic Neuroendocrine Tumors: CT Features and Texture Analysis in the Prediction of Tumor Grade and F-FDG Uptake. *Cancers*, **2020**, 12,	6.6	3
574	Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases. *Endoscopy*, **2020**, 52, 988-994	3.4	14
573	Molecular Tumor Boards in Clinical Practice. *Trends in Cancer*, **2020**, 6, 738-744	12.5	29
572	Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients. *Updates in Surgery*, **2020**, 72, 119-128	2.9	5
571	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. *Cells*, **2020**, 9,	7.9	14
570	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. *Breast*, **2020**, 50, 56-63	3.6	3
569	Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. *Pancreatology*, **2020**, 20, 586-593	3.8	22
568	Impact of image analysis and artificial intelligence in thyroid pathology, with particular reference to cytological aspects. *Cytopathology*, **2020**, 31, 432-444	1.3	12
567	Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1009-1018	4	15
566	Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. *Annals of Surgery*, **2020**,	7.8	4
565	The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation. *EMBO Reports*, **2020**, 21, e50078	6.5	11

564	Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. *Pathologica*, **2020**, 112, 248-259	1.9	11
563	Malignant epithelial/exocrine tumors of the pancreas. *Pathologica*, **2020**, 112, 210-226	1.9	4
562	Inflammatory and tumor-like lesions of the pancreas. *Pathologica*, **2020**, 112, 197-209	1.9	3
561	Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 247-257	6.1	22
560	Diagnostic concordance between whole slide imaging and conventional light microscopy in cytopathology: A systematic review. *Cancer Cytopathology*, **2020**, 128, 17-28	3.9	24
559	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. *Hepatology*, **2020**, 72, 982-996	11.2	21
558	Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing. *Neuropathology*, **2020**, 40, 68-74	2	6
557	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Annals of Oncology*, **2020**, 31, 1491-1505	19.3	223
556	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages. *Cancer Discovery*, **2020**, 10, 1758-1773	24.4	17
555	Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	11
554	KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 227	12.8	18
553	Genomic characterization of malignant progression in neoplastic pancreatic cysts. *Nature Communications*, **2020**, 11, 4085	17.4	27
552	CD117 Is a Specific Marker of Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas, Oncocytic Subtype. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
551	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. *Cancers*, **2020**, 12,	6.6	19
550	Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study. *Biomedicines*, **2020**, 8,	4.8	1
549	Placenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors. *Neuroendocrinology*, **2020**, 110, 23-34	5.6	7
548	Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. *Annals of Surgery*, **2020**, 271, 566-573	7.8	42
547	Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, **2020**, 27, 3898-3912	3.1	6

546	Ultra-Mutation in Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. *Cancers*, **2019**, 11,	6.6	12
545	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 **2019**, 7, 255		81
544	Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. *International Journal of Cancer*, **2019**, 145, 686-693	7.5	15
543	JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 28	12.8	12
542	Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. *Cancers*, **2019**, 11,	6.6	23
541	Muscle derangement and alteration of the nutritional machinery in NSCLC. *Critical Reviews in Oncology/Hematology*, **2019**, 141, 43-53	7	10
540	Preclinical Modelling of PDA: Is Organoid the New Black?. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	7
539	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. *Journal of Thoracic Oncology*, **2019**, 14, 1651-1661	8.9	44
538	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. *Scientific Reports*, **2019**, 9, 7665	4.9	23
537	The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. *Annales DiEndocrinologie*, **2019**, 80, 153-158	1.7	33
536	EUS-FNB with or without on-site evaluation for the diagnosis of solid pancreatic lesions (FROSENOR): Protocol for a multicenter randomized non-inferiority trial. *Digestive and Liver Disease* , **2019**, 51, 901-906	3.3	14
535	ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. *Annals of Oncology*, **2019**, 30, 1232-1243	10.3	256
534	Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. *Cancers*, **2019**, 11,	6.6	14
533	The Italian Rare Pancreatic Exocrine Cancer Initiative. *Tumori*, **2019**, 105, 353-358	1.7	3
532	Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential. *Journal of the American College of Surgeons*, **2019**, 228, 721-729	4.4	23
531	CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 474, 105-109	5.1	15
530	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. *Cancers*, **2019**, 11,	6.6	25
529	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. *Cancers*, **2019**, 11,	6.6	47

528	Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. *Scientific Reports*, **2019**, 9, 12286	4.9	15
527	Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?. *Hpb*, **2019**, 21, 1648-1655	3.8	4
526	A multimodality test to guide the management of patients with a pancreatic cyst. *Science Translational Medicine*, **2019**, 11,	17.5	71
525	CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients. *Annals of Hematology*, **2019**, 98, 2339-2346	3	3
524	The integrin drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. *Journal of Pathology*, **2019**, 249, 332-342	9.4	34
523	Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma. *Neuropathology*, **2019**, 39, 474-478	2	4
522	Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. *Endocrine Reviews*, **2019**, 40, 506-536	27.2	87
521	CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms. *Scientific Reports*, **2019**, 9, 2176	4.9	36
520	Management of Thyroid Nodules in Deceased Donors With Comparison Between Fine Needle Aspiration and Intraoperative Frozen Section in the Setting of Transplantation. *Progress in Transplantation*, **2019**, 29, 316-320	1.1	2
519	Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. *International Journal of Cancer*, **2019**, 144, 1540-1549	7.5	4
518	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). *Neuroendocrinology*, **2019**, 108, 54-62	5.6	41
517	How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation Network. *Journal of Nephrology*, **2019**, 32, 323-330	4.8	10
516	Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome. *Cancer Immunology Research*, **2019**, 7, 12-28	12.5	18
515	Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. *Modern Pathology*, **2019**, 32, 659-665	9.8	14
514	Histologic retrieval rate of a newly designed side-bevelled 20G needle for EUS-guided tissue acquisition of solid pancreatic lesions. *United European Gastroenterology Journal*, **2019**, 7, 96-104	5.3	28
513	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. *Pancreas*, **2019**, 48, 70-76	2.6	4
512	Touch imprint cytology on endoscopic ultrasound fine-needle biopsy provides comparable sample quality and diagnostic yield to standard endoscopic ultrasound fine-needle aspiration specimens in the evaluation of solid pancreatic lesions. *Cytopathology*, **2019**, 30, 179-186	1.3	24
511	Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and Where?. *Neuroendocrinology*, **2019**, 108, 161-171	5.6	31

510	Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. *Journal of Pathology*, **2019**, 247, 123-134	9.4	22
509	The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. *Annals of Surgery*, **2019**, 269, 725-732	7.8	35
508	Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report. *Oncology Letters*, **2019**, 17, 462-467	2.6	1
507	Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. *Human Pathology*, **2018**, 75, 167-178	3.7	9
506	Combined adenocarcinoma□typical carcinoid of the lung. Targeted Next-Generation Sequencing (NGS) suggests a monoclonal origin of the two components. *Diagnostic Histopathology*, **2018**, 24, 120-123	0.7	7
505	Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management. *Gut*, **2018**, 67, 1561-1563	19.2	12
504	Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. *International Journal of Epidemiology*, **2018**, 47, 473-483	7.8	20
503	Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. *Pancreatology*, **2018**, 18, 420-428	3.8	23
502	Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas. *Surgery*, **2018**, 163, 1272-1279	3.6	42
501	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 472, 567-577	5.1	41
500	Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. *Journal of Hepatology*, **2018**, 68, 959-969	13.4	149
499	Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors?. *European Radiology*, **2018**, 28, 2582-2591	8	44
498	Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 472, 939-947	5.1	19
497	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. *Journal of Thoracic Oncology*, **2018**, 13, 568-575	8.9	9
496	Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. *Journal of Endocrinology*, **2018**, 236, R161-R167	4.7	46
495	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. *Annals of Oncology*, **2018**, 29, 30-35	10.3	57
494	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. *Endocrine-Related Cancer*, **2018**, 25, 583-593	5.7	55
493	Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity Results from a Single-Center Surgical Series. *Neuroendocrinology*, **2018**, 106, 234-241	5.6	12

492	Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. *Annals of Surgery*, **2018**, 267, 149-156	7.8	24
491	Non-coding regulatory variations: the dark matter of pancreatic cancer genomics. *Gut*, **2018**, 67, 399-400	19.2	3
490	FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. *Oncogene*, **2018**, 37, 697-709	9.2	35
489	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. *Carcinogenesis*, **2018**, 39, 971-980	4.6	32
488	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 140	12.8	22
487	Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. *BMC Genomics*, **2018**, 19, 440	4.5	10
486	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. *Human Pathology*, **2018**, 81, 157-165	3.7	23
485	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. *Scientific Reports*, **2018**, 8, 7119	4.9	25
484	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Modern Pathology*, **2018**, 31, 1770-1786	9.8	428
483	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. *BMC Cancer*, **2018**, 18, 828	4.8	15
482	Beyond Pancreatic Cyst Epithelium: Evidence of Ovarian-Like Stroma in EUS-Guided Through-the-Needle Micro-Forceps Biopsy Specimens. *American Journal of Gastroenterology*, **2018**, 113, 1059-1060	0.7	14
481	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.. *Journal of Clinical Oncology*, **2018**, 36, 542-542	2.2	1
480	MicroRNA signatures and Foxp3 cell count correlate with relapse occurrence in follicular lymphoma. *Oncotarget*, **2018**, 9, 19961-19979	3.3	10
479	High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids. *Oncotarget*, **2018**, 9, 27535-27546	3.3	2
478	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. *Oncotarget*, **2018**, 9, 29753-29771	3.3	9
477	Validation of Remote Digital Frozen Sections for Cancer and Transplant Intraoperative Services. *Journal of Pathology Informatics*, **2018**, 9, 34	4.4	26
476	Innovation in Transplantation: The Digital Era. *Journal of Pathology Informatics*, **2018**, 9, 33	4.4	2
475	Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma. *World Journal of Gastrointestinal Oncology*, **2018**, 10, 317-327	3.4	18

474	Pathological Analysis of Abdominal Neuroendocrine Tumors. *Updates in Surgery Series*, **2018**, 123-135	0.1	
473	Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. *Langenbeckis Archives of Surgery*, **2018**, 403, 213-220	3.4	9
472	Classification of Abdominal Neuroendocrine Tumors. *Updates in Surgery Series*, **2018**, 21-32	0.1	
471	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. *Gastroenterology*, **2018**, 154, 1066-1079.e5	13.3	61
470	Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. *International Journal of Obesity*, **2018**, 42, 334-343	5.5	22
469	Ampulla of Vater carcinoma: Molecular landscape and clinical implications. *World Journal of Gastrointestinal Oncology*, **2018**, 10, 370-380	3.4	19
468	Frequent fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. *Oncotarget*, **2018**, 9, 9661-9671	3.3	23
467	Induction of immunosuppressive functions and NF-B by FLIP in monocytes. *Nature Communications*, **2018**, 9, 5193	17.4	31
466	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. *Neuroendocrinology*, **2018**, 107, 375-386	5.6	52
465	Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 473, 709-717	5.1	21
464	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. *Pathology Research and Practice*, **2018**, 214, 1675-1680	3.4	1
463	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. *Journal of Thoracic Oncology*, **2018**, 13, 1692-1704	8.9	49
462	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. *Targeted Oncology*, **2018**, 13, 649-655	5	13
461	Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. *Molecular Cancer Research*, **2018**, 16, 1385-1395	6.6	7
460	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. *Pancreas*, **2018**, 47, 759-771	2.6	20
459	Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. *Modern Pathology*, **2018**, 31, 1532-1538	9.8	15
458	Soluble stroma-related biomarkers of pancreatic cancer. *EMBO Molecular Medicine*, **2018**, 10,	12	30
457	Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. *International Journal of Cancer*, **2018**, 142, 1010-1021	7.5	6

456	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. *Gut*, **2017**, 66, 314-322	19.2	37
455	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. *Gut*, **2017**, 66, 1268-1277	19.2	58
454	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. *Scientific Reports*, **2017**, 7, 43013	4.9	36
453	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. *Critical Reviews in Oncology/Hematology*, **2017**, 111, 152-165	7	26
452	Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature*, **2017**, 543, 65-71	50.4	482
451	PBRM1 loss is a late event during the development of cholangiocarcinoma. *Histopathology*, **2017**, 71, 375-382	7.3	15
450	A circulating T2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. *OncoImmunology*, **2017**, 6, e1322242	7.2	23
449	Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. *Cancer Genetics*, **2017**, 210, 28-33	2.3	2
448	Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions. *Pancreas*, **2017**, 46, 42-47	2.6	26
447	Fast Chromotrope Aniline Blue Special Stain Is a Useful Tool to Assess Fibrosis on Liver Biopsy During Transplantation. *Transplantation Proceedings*, **2017**, 49, 667-670	1.1	4
446	Splice variants as novel targets in pancreatic ductal adenocarcinoma. *Scientific Reports*, **2017**, 7, 2980	4.9	21
445	An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors. *OncoImmunology*, **2017**, 6, e1326437	7.2	23
444	Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. *Breast*, **2017**, 35, 21-26	3.6	12
443	Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. *Scientific Reports*, **2017**, 7, 2374	4.9	19
442	Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. *Annals of Surgery*, **2017**, 266, 133-141	7.8	79
441	Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. *Annals of Surgery*, **2017**, 266, 142-148	7.8	60
440	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). *Journal of Thoracic Oncology*, **2017**, 12, S266-S267	8.9	4
439	Fhit down-regulation is an early event in pancreatic carcinogenesis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 647-653	5.1	4

438	A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. *Annals of Oncology*, **2017**, 28, 1618-1624	10.3	15
437	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. *Annals of Oncology*, **2017**, 28, 1243-1249	10.3	17
436	Clear cell colorectal carcinoma: Time to clarify diagnosis. *Pathology Research and Practice*, **2017**, 213, 447-452	3.4	10
435	ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. *Cancer Biomarkers*, **2017**, 18, 215-220	3.8	3
434	ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma. *Journal of Thoracic Oncology*, **2017**, 12, e161-e163	8.9	13
433	UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism. *Free Radical Biology and Medicine*, **2017**, 113, 176-189	7.8	40
432	Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. *Oncotarget*, **2017**, 8, 7328-7335	3.3	16
431	Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors. *World Journal of Gastroenterology*, **2017**, 23, 3092-3098	5.6	5
430	Pancreatectomy with venous resection for pT3 head adenocarcinoma: Perioperative outcomes, recurrence pattern and prognostic implications of histologically confirmed vascular infiltration. *Pancreatology*, **2017**, 17, 847-857	3.8	28
429	Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. *Journal of Pathology*, **2017**, 243, 148-154	9.4	50
428	Rapid screening for malignancy in organ donors: 15-year experience with the Verona "Alert" protocol and review of the literature. *Clinical Transplantation*, **2017**, 31, e13045	3.8	9
427	Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. *Annals of Oncology*, **2017**, 28, 2896-2898	10.3	9
426	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. *Cancer Discovery*, **2017**, 7, 1116-1135	24.4	368
425	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. *Journal of Pathology*, **2017**, 241, 488-500	9.4	122
424	Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. *Journal of Proteomics*, **2017**, 150, 310-322	3.9	63
423	A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database. *Journal of Gastrointestinal Surgery*, **2017**, 21, 41-48	3.3	28
422	Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer. *Journal of Gastrointestinal Surgery*, **2017**, 21, 527-533	3.3	4
421	Hypermutation In Pancreatic Cancer. *Gastroenterology*, **2017**, 152, 68-74.e2	13.3	130

420	Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material. *Oncotarget*, **2017**, 8, 108223-108237	3.3	5
419	Immune landscape of pancreatic neuroendocrine tumours (PanNETs). *Annals of Oncology*, **2017**, 28, v142	10.3	5
418	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	33
417	Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. *Oncotarget*, **2017**, 8, 11809-11826	3.3	11
416	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. *Oncotarget*, **2017**, 8, 13611-13619	3.3	66
415	MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. *Annals of Translational Medicine*, **2017**, 5, 2	3.2	32
414	Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment. *Anticancer Research*, **2017**, 37, 1305-1311	2.3	6
413	Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage. *World Journal of Gastroenterology*, **2017**, 23, 275-285	5.6	29
412	Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis. *Annals of Oncology*, **2016**, 27, 42-8	10.3	52
411	Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: a systematic review and meta-analysis of its prognostic significance. *European Journal of Gastroenterology and Hepatology*, **2016**, 28, 205-9	2.2	35
410	Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. *Gastroenterology*, **2016**, 151, 1218-1231	13.3	78
409	Solid pseudopapillary tumors of the pancreas: Specific pathological features predict the likelihood of postoperative recurrence. *Journal of Surgical Oncology*, **2016**, 114, 597-601	2.8	49
408	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. *Endocrine Connections*, **2016**, 5, 174-87	3.5	63
407	The impact of immunohistochemistry on the classification of lung tumors. *Expert Review of Respiratory Medicine*, **2016**, 10, 1105-21	3.8	12
406	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. *Targeted Oncology*, **2016**, 11, 569-577	5	12
405	Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. *Scientific Reports*, **2016**, 6, 22982	4.9	13
404	An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. *Clinical Cancer Research*, **2016**, 22, 6164-6175	12.9	48
403	RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes. *BMC Cancer*, **2016**, 16, 11	4.8	11

402	Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses. *BMC Cancer*, **2016**, 16, 195	4.8	6
401	Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. *Annals of Surgical Oncology*, **2016**, 23, 1699-707	3.1	52
400	Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma. *Medicine (United States)*, **2016**, 95, e2491	1.8	39
399	Extranodal extension is an important prognostic parameter for both colonic and rectal cancer. *Annals of Oncology*, **2016**, 27, 955-6	10.3	23
398	Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. *Surgery*, **2016**, 159, 862-71	3.6	52
397	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. *Critical Reviews in Oncology/Hematology*, **2016**, 98, 309-24	7	30
396	Secretome protein signature of human pancreatic cancer stem-like cells. *Journal of Proteomics*, **2016**, 136, 1-12	3.9	51
395	Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*, **2016**, 531, 47-52	50.4	1785
394	Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging. *Neuroendocrinology*, **2016**, 103, 758-70	5.6	19
393	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. *Targeted Oncology*, **2016**, 11, 345-51	5	48
392	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. *Pancreatology*, **2016**, 16, 14-27	3.8	49
391	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. *Oncotarget*, **2016**, 7, 1076-83	3.3	58
390	miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma. *Oncotarget*, **2016**, 7, 28195-206	3.3	26
389	New genomic landscapes and therapeutic targets for biliary tract cancers. *Frontiers in Bioscience - Landmark*, **2016**, 21, 707-18	2.8	3
388	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. *OncoTargets and Therapy*, **2016**, 9, 4681-6	4.4	7
387	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. *Oncotarget*, **2016**, 7, 66328-66343	3.3	66
386	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. *Respiratory Research*, **2016**, 17, 105	7.3	9
385	Combined inhibition of IL1, CXCR1/2, and TGF signaling pathways modulates in-vivo resistance to anti-VEGF treatment. *Anti-Cancer Drugs*, **2016**, 27, 29-40	2.4	25

384	N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes. *Hematological Oncology*, **2016**, 34, 79-83	1.3	2
383	Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis. *Genes Chromosomes and Cancer*, **2016**, 55, 741-9	5	49
382	The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome. *OncoImmunology*, **2016**, 5, e1221556	7.2	15
381	Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. *Journal of Clinical Pathology*, **2016**, 69, 956-961	3.9	24
380	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. *Scientific Reports*, **2016**, 6, 39565	4.9	9
379	Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis. *Cancer Letters*, **2016**, 376, 303-9	9.9	40
378	Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression. *Cancer Research*, **2016**, 76, 4149-59	10.1	67
377	Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis. *Surgical Oncology*, **2016**, 25, 60-5	2.5	42
376	Significance of the prognostic stratification of extranodal extension in colorectal cancer. *Annals of Oncology*, **2016**, 27, 1647	10.3	8
375	Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. *Bone*, **2016**, 92, 150-156	4.7	31
374	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2253-2266	4	22
373	Pancreatic Ductal Adenocarcinoma and Its Variants. *Surgical Pathology Clinics*, **2016**, 9, 547-560	3.9	69
372	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. *Carcinogenesis*, **2016**, 37, 957-64	4.6	13
371	Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*, **2015**, 518, 495-501	50.4	1579
370	Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2015**, 56, 1897-900	1.9	3
369	Pancreatic cancer growth using magnetic resonance and bioluminescence imaging. *Magnetic Resonance Imaging*, **2015**, 33, 592-9	3.3	3
368	A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology*, **2015**, 149, 1501-10	13.3	286
367	Reappraisal of Nodal Staging and Study of Lymph Node Station Involvement in Pancreaticoduodenectomy with the Standard International Study Group of Pancreatic Surgery Definition of Lymphadenectomy for Cancer. *Journal of the American College of Surgeons*, **2015**, 221, 367-79.e4	4.4	61

366	Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors?. *European Journal of Surgical Oncology*, **2015**, 41, 1162-9	3.6	46
365	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nature Genetics*, **2015**, 47, 911-6	36.3	171
364	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. *BMC Cancer*, **2015**, 15, 26	4.8	42
363	Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. *Radiology and Oncology*, **2015**, 49, 147-54	3.8	40
362	Identification of MicroRNAs Differentially Expressed in Lung Carcinoid Subtypes and Progression. *Neuroendocrinology*, **2015**, 101, 246-55	5.6	37
361	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy. *Anti-Cancer Drugs*, **2015**, 26, 469-73	2.4	0
360	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. *Cancer Discovery*, **2015**, 5, 1296-313	24.4	100
359	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. *Hereditary Cancer in Clinical Practice*, **2015**, 13, 18	2.3	26
358	Whole-Genome/Exome Sequencing in Acute Leukemia: From Research to Clinics **2015**, 381-400		3
357	In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors. *Neoplasia*, **2015**, 17, 473-80	6.4	13
356	Neuroendocrine Neoplasms **2015**, 103-193		
355	Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. *Modern Pathology*, **2015**, 28, 69-79	9.8	17
354	Stratification of pancreatic tissue samples for molecular studies: RNA-based cellular annotation procedure. *Pancreatology*, **2015**, 15, 423-31	3.8	4
353	Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis. *Journal of Surgical Oncology*, **2015**, 112, 828-33	2.8	32
352	TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. *International Journal of Cancer*, **2015**, 137, 2175-83	7.5	46
351	MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7. *Oncotarget*, **2015**, 6, 21802-15	3.3	59
350	Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. *International Journal of Biological Markers*, **2015**, 30, e136-41	2.8	32
349	Meninges harbor cells expressing neural precursor markers during development and adulthood. *Frontiers in Cellular Neuroscience*, **2015**, 9, 383	6.1	31

348	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. *PLoS ONE*, **2015**, 10, e0130142	3.7	339
347	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. *Oncotarget*, **2015**, 6, 23323-41	3.3	55
346	ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature. *American Journal of Surgical Pathology*, **2015**, 39, 374-82	6.7	50
345	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. *American Heart Journal*, **2015**, 169, 631-638.e7	4.9	72
344	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. *Journal of Thoracic Oncology*, **2015**, 10, 1341-1348	8.9	13
343	Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. *International Journal of Oncology*, **2015**, 46, 1099-108	4.4	35
342	Genetics and Epigenetics of Pancreatic Neuroendocrine Tumors and Pulmonary Carcinoids. *Frontiers of Hormone Research*, **2015**, 44, 115-38	3.5	4
341	Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-□to-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.	3	5
340	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Annals of Oncology*, **2015**, 26, 1604-20	10.3	363
339	Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. *Journal of the American College of Surgeons*, **2015**, 220, 243-53	4.4	50
338	An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. *Oncotarget*, **2015**, 6, 13822-34	3.3	36
337	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. *Oncotarget*, **2015**, 6, 12783-95	3.3	44
336	Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. *American Journal of Cancer Research*, **2015**, 5, 2212-21	4.4	
335	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. *Oncotarget*, **2015**, 6, 39088-97	3.3	49
334	Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. *Oncotarget*, **2015**, 6, 32061-74	3.3	9
333	MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis. *Current Drug Targets*, **2015**, 16, 383-92	3	17
332	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. *World Journal of Gastroenterology*, **2015**, 21, 4788-801	5.6	48
331	Molecular Biology of Neuroendocrine Tumors **2015**, 35-49		1

330	Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era **2015**, 367-379		
329	Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. *Journal of the National Cancer Institute*, **2014**, 106, djt347	9.7	191
328	High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2014**, 465, 73-8	5.1	48
327	MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E374-8	5.6	44
326	Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. *Endocrine Pathology*, **2014**, 25, 151-64	4.2	35
325	hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications. *Clinical Cancer Research*, **2014**, 20, 1502-12	12.9	38
324	RAF signaling in neuroendocrine neoplasms: from bench to bedside. *Cancer Treatment Reviews*, **2014**, 40, 974-9	14.4	16
323	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nature Genetics*, **2014**, 46, 994-1000	36.3	226
322	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. *Nature Methods*, **2014**, 11, 1161-9	21.6	131
321	Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. *Cancer and Metastasis Reviews*, **2014**, 33, 345-51	9.6	24
320	Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. *Surgery*, **2014**, 155, 145-53	3.6	67
319	Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. *Molecules*, **2014**, 19, 2458-68	4.8	32
318	Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells. *British Journal of Cancer*, **2014**, 111, 1780-7	8.7	50
317	Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. *Journal of Pathology*, **2014**, 233, 217-27	9.4	240
316	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. *International Journal of Cancer*, **2014**, 135, 1110-8	7.5	149
315	iPathology cockpit diagnostic station: validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the Hospital Trust and University of Verona. *Diagnostic Pathology*, **2014**, 9 Suppl 1, S12	3	31
314	A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. *Genome Medicine*, **2014**, 6, 105	14.4	76
313	ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. *Journal of Thoracic Oncology*, **2014**, 9, 729-32	8.9	39

312	Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. *Pancreas*, **2014**, 43, 212-8	2.6	38
311	Next-generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma. *Journal of Clinical Oncology*, **2014**, 32, e63-6	2.2	46
310	Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. *Neuroendocrinology*, **2014**, 100, 310-6	5.6	93
309	VEGF-A clinical significance in gastric cancers: immunohistochemical analysis of a wide Italian cohort. *European Journal of Surgical Oncology*, **2014**, 40, 1291-8	3.6	3
308	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. *Gastric Cancer*, **2014**, 17, 442-9	7.6	45
307	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel **2014**,		4
306	Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. *PLoS ONE*, **2014**, 9, e88525	3.7	58
305	Reporting tumor molecular heterogeneity in histopathological diagnosis. *PLoS ONE*, **2014**, 9, e104979	3.7	34
304	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. *Oncotarget*, **2014**, 5, 2839-52	3.3	134
303	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. *Oncotarget*, **2014**, 5, 6611-9	3.3	49
302	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. *American Journal of Cancer Research*, **2014**, 4, 907-15	4.4	3
301	Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice. *Current Medicinal Chemistry*, **2014**, 21, 1017-25	4.3	8
300	Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. *Current Pharmaceutical Design*, **2014**, 20, 3958-72	3.3	10
299	Prognostic value of ALK gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. *Journal of Clinical Oncology*, **2014**, 32, e19059-e19059	2.2	
298	Profiling mTOR Pathway in Neuroendocrine Tumors **2014**, 9-27		
297	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nature Genetics*, **2013**, 45, 1470-1473	36.3	464
296	Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. *Digestive and Liver Disease*, **2013**, 45, 95-9	3.3	34
295	Ectopic expression of the heterotrimeric G15 protein in pancreatic carcinoma and its potential in cancer signal transduction. *Cellular Signalling*, **2013**, 25, 651-9	4.9	4

294	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. *Journal of Hematology and Oncology*, **2013**, 6, 67	22.4	35
293	Ezrin expression is an independent prognostic factor in gastro-intestinal cancers. *Journal of Gastrointestinal Surgery*, **2013**, 17, 2082-91	3.3	11
292	Do matrix metalloproteinase-1 and glucose-6-phosphate dehydrogenase gene polymorphisms interact in promoting lymphoma development?. *Leukemia and Lymphoma*, **2013**, 54, 2734-5	1.9	
291	Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. *Journal of Clinical Oncology*, **2013**, 31, 1348-56	2.2	112
290	Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. *Clinical Cancer Research*, **2013**, 19, 2842-9	12.9	69
289	Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. *Biochimica Et Biophysica Acta - Biomembranes*, **2013**, 1828, 1396-404	3.8	54
288	A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. *Annals of Oncology*, **2013**, 24, 693-701	10.3	50
287	Reply to G.F. Arroyo. *Journal of Clinical Oncology*, **2013**, 31, 3843-4	2.2	
286	Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. *International Journal of Molecular Sciences*, **2013**, 14, 19731-62	6.3	39
285	ICAT is a novel Ptf1a interactor that regulates pancreatic acinar differentiation and displays altered expression in tumours. *Biochemical Journal*, **2013**, 451, 395-405	3.8	5
284	Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). *JAMA Surgery*, **2013**, 148, 932-9	5.4	121
283	EU Pancreas: an integrated European platform for pancreas cancer research--from basic science to clinical and public health interventions for a rare disease. *Public Health Genomics*, **2013**, 16, 305-12	1.9	1
282	Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. *British Journal of Cancer*, **2013**, 109, 686-93	8.7	20
281	BAG3 is a novel serum biomarker for pancreatic adenocarcinomas. *American Journal of Gastroenterology*, **2013**, 108, 1178-80	0.7	25
280	DNA qualification workflow for next generation sequencing of histopathological samples. *PLoS ONE*, **2013**, 8, e62692	3.7	164
279	Pathologist's Role in the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). *The Journal of Oncopathology*, **2013**, 1, 65-74		2
278	Somatic mutations in exocrine pancreatic tumors: association with patient survival. *PLoS ONE*, **2013**, 8, e60870	3.7	34
277	A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. *PLoS ONE*, **2013**, 8, e68203	3.7	10

276	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. *PLoS ONE*, **2013**, 8, e80478	3.7	88
275	Pancreatic Cancer Genomics **2013**, 219-253		1
274	Pathology and Genetics. *Updates in Surgery Series*, **2013**, 71-78	0.1	
273	HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. *Anticancer Research*, **2013**, 33, 3705-10	2.3	2
272	TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. *Journal of the National Cancer Institute*, **2012**, 104, 764-77	9.7	362
271	Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality. *Journal of Molecular Diagnostics*, **2012**, 14, 30-7	5.1	19
270	Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. *Neuroendocrinology*, **2012**, 96, 32-40	5.6	44
269	Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. *European Journal of Cancer*, **2012**, 48, 1608-15	7.5	122
268	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature*, **2012**, 491, 399-405	36.4	1427
267	Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. *American Journal of Pathology*, **2012**, 181, 1524-9	5.8	48
266	Profiling mTOR pathway in neuroendocrine tumors. *Targeted Oncology*, **2012**, 7, 183-8	5	32
265	Pathology - grading and staging of GEP-NETs. *Bailliereis Best Practice and Research in Clinical Gastroenterology*, **2012**, 26, 705-17	2.5	48
264	Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. *Surgical Oncology*, **2012**, 21, e171-82	2.5	13
263	Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. *PLoS ONE*, **2012**, 7, e46002	3.7	52
262	Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. *Journal of Proteome Research*, **2012**, 11, 1274-83	5.6	55
261	Differentiation of multiple types of pancreatico-biliary tumors by molecular analysis of clinical specimens. *Journal of Molecular Medicine*, **2012**, 90, 457-64	5.5	6
260	Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. *Annals of Oncology*, **2012**, 23, 127-134	10.3	49
259	Molecular pathology of pancreatic cancer: from bench-to-bedside translation. *Current Drug Targets*, **2012**, 13, 744-52	3	26

258	KRAS aKtive, an Italian network for assessment of KRAS mutations in colorectal cancer patients: Results on 7,432 cases.. *Journal of Clinical Oncology*, **2012**, 30, e14042-e14042	2.2	
257	Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: A clinical-biological risk stratification model.. *Journal of Clinical Oncology*, **2012**, 30, 4076-4076	2.2	
256	Circulating autoantibodies to phosphorylated □enolase are a hallmark of pancreatic cancer. *Journal of Proteome Research*, **2011**, 10, 105-12	5.6	96
255	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. *Cell Death and Disease*, **2011**, 2, e152	9.8	165
254	Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy. *Haematologica*, **2011**, 96, 24-32	6.6	26
253	Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. *Surgery*, **2011**, 150, 75-82	3.6	238
252	Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. *BMC Cancer*, **2011**, 11, 351	4.8	55
251	Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. *Free Radical Biology and Medicine*, **2011**, 50, 926-33	7.8	23
250	Aggressive approach to acinar cell carcinoma of the pancreas: a single-institution experience and a literature review. *Langenbeckis Archives of Surgery*, **2011**, 396, 363-9	3.4	46
249	Chromosome 3p alterations in pancreatic endocrine neoplasia. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2011**, 458, 39-45	5.1	14
248	Pseudopapillary tumor in pediatric age: clinical and surgical management. *Pediatric Surgery International*, **2011**, 27, 1271-5	2.1	25
247	Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. *BMC Cancer*, **2011**, 11, 448	4.8	31
246	MET mutations in cancers of unknown primary origin (CUPs). *Human Mutation*, **2011**, 32, 44-50	4.7	57
245	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. *Clinical Cancer Research*, **2011**, 17, 6531-41	12.9	42
244	Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. *Journal of Clinical Oncology*, **2011**, 29, 2372-7	2.2	216
243	Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. *Annals of Oncology*, **2011**, 22, 482-4	10.3	8
242	Presentation and outcome of pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1 syndrome. *Neuroendocrinology*, **2011**, 94, 58-65	5.6	36
241	Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. *Endocrine-Related Cancer*, **2011**, 18, 541-54	5.7	31

240	Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. *Bioscience Reports*, **2011**, 31, 45-55	4.1	58
239	Immunohistochemical detection of arginine methylated proteins (MeRP) in archival tissues. *Histopathology*, **2010**, 57, 725-33	7.3	4
238	Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. *British Journal of Cancer*, **2010**, 103, 391-400	8.7	41
237	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
236	Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. *PLoS ONE*, **2010**, 5, e12653	3.7	11
235	Pathology and Genetics. *Medical Radiology*, **2010**, 11-18	0.2	
234	MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. *Endocrine-Related Cancer*, **2010**, 17, 771-83	5.7	110
233	Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. *Journal of Clinical Oncology*, **2010**, 28, 245-55	2.2	427
232	Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. *Modern Pathology*, **2010**, 23, 824-33	9.8	338
231	Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. *Neuroendocrinology*, **2010**, 92, 246-51	5.6	60
230	RHOA and PRKCZ control different aspects of cell motility in pancreatic cancer metastatic clones. *Molecular Cancer*, **2010**, 9, 61	42.1	13
229	Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. *Journal of Translational Medicine*, **2010**, 8, 10	8.5	35
228	The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. *Journal of Experimental and Clinical Cancer Research*, **2010**, 29, 32	12.8	48
227	Multicentre validation study of nucleic acids extraction from FFPE tissues. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2010**, 457, 309-17	5.1	82
226	Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. *Anticancer Research*, **2010**, 30, 4269-81	2.3	28
225	Mutational profile of GNAQQ209 in human tumors. *PLoS ONE*, **2009**, 4, e6833	3.7	57
224	Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. *American Journal of Gastroenterology*, **2009**, 104, 3034-41	0.7	39
223	MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. *Nucleic Acids Research*, **2009**, 37, 6681-90	20.1	50

222	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. *Neuroendocrinology*, **2009**, 90, 167-83	5.6	212
221	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. *Neuroendocrinology*, **2009**, 90, 209-13	5.6	51
220	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. *Neuroendocrinology*, **2009**, 90, 184-9	5.6	142
219	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: echocardiography. *Neuroendocrinology*, **2009**, 90, 190-3	5.6	44
218	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. *Neuroendocrinology*, **2009**, 90, 203-8	5.6	32
217	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. *Neuroendocrinology*, **2009**, 90, 220-6	5.6	131
216	Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. *Neuroendocrinology*, **2009**, 89, 223-30	5.6	41
215	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. *Neuroendocrinology*, **2009**, 90, 227-33	5.6	103
214	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. *Neuroendocrinology*, **2009**, 90, 214-9	5.6	79
213	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. *Neuroendocrinology*, **2009**, 90, 162-6	5.6	263
212	Intracellular zinc increase inhibits p53(-/-) pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2009**, 1793, 273-80	4.9	33
211	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. *Human Mutation*, **2009**, 30, E451-9	4.7	37
210	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Human Mutation*, **2009**, 30, 7-11	4.7	320
209	Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. *Human Mutation*, **2009**, 30, 1167-74	4.7	34
208	An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. *International Journal of Cancer*, **2009**, 125, 639-48	7.5	88
207	Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. *Proteomics*, **2009**, 9, 1952-66	4.8	34
206	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. *Neuroendocrinology*, **2009**, 90, 194-202	5.6	187
205	Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. *Digestive and Liver Disease*, **2009**, 41, 49-55	3.3	64

204	Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma. *Pancreatology*, **2009**, 9, 25-33	3.8	22
203	Innovative electrochemical approach for an early detection of microRNAs. *Analytical Chemistry*, **2009**, 81, 2819-22	7.8	111
202	Expression pattern of claudins 5 and 7 distinguishes solid-pseudopapillary from pancreatoblastoma, acinar cell and endocrine tumors of the pancreas. *American Journal of Surgical Pathology*, **2009**, 33, 768-74	6.7	45
201	Endocrine neoplasms of the pancreas: pathologic and genetic features. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 350-64	5	71
200	Nonneoplastic mimickers of pancreatic neoplasms. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 439-53	5	39
199	AKT1(E17K) in human solid tumours. *Oncogene*, **2008**, 27, 5648-50	9.2	165
198	Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. *Neuroendocrinology*, **2008**, 87, 40-6	5.6	60
197	Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. *Neuroendocrinology*, **2008**, 87, 8-19	5.6	198
196	Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. *Neuroendocrinology*, **2008**, 87, 31-9	5.6	90
195	Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. *Neuroendocrinology*, **2008**, 87, 47-62	5.6	240
194	Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. *FASEB Journal*, **2008**, 22, 1849-60	0.9	27
193	Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. *Annals of Oncology*, **2008**, 19, 903-8	10.3	177
192	Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. *Neuroendocrinology*, **2008**, 87, 20-30	5.6	95
191	Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. *Haematologica*, **2008**, 93, 524-32	6.6	43
190	Clinical and radiological outcome of patients suffering from chronic pancreatitis associated with gene mutations. *Pancreas*, **2008**, 37, 371-6	2.6	3
189	Identification of a candidate alternative promoter region of the human Bcl2L11 (Bim) gene. *BMC Molecular Biology*, **2008**, 9, 56	4.5	6
188	Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. *Hematological Oncology*, **2008**, 26, 98-103	1.3	41
187	Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. *Journal of Cellular Biochemistry*, **2008**, 104, 202-12	4.7	29

186	Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. *Annals of Surgical Oncology*, **2008**, 15, 3178-86	3.1	75
185	Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. *Journal of Clinical Investigation*, **2008**, 118, 1924-33	15.9	104
184	Phosphodiesterase-4 Inhibition Reduces Ischemic/Reperfusion Liver Injury in a Mouse Model for Sickle Cell Disease.. *Blood*, **2008**, 112, 1444-1444	2.2	
183	Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors. *Neoplasia*, **2007**, 9, 181-3	6.4	29
182	Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. *Proteomics*, **2007**, 7, 1644-53	4.8	31
181	Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. *Oncogene*, **2007**, 26, 7590-5	9.2	342
180	Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. *Modern Pathology*, **2007**, 20, 722-8	9.8	58
179	Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues. *Histopathology*, **2007**, 50, 615-28	7.3	26
178	Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2007**, 1773, 1095-106	4.9	117
177	TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2007**, 451, 757-62	5.1	741
176	Adenocarcinoma of the ampulla of Vater: T-stage, chromosome 17p allelic loss, and extended pancreaticoduodenectomy are relevant prognostic factors. *Journal of Gastrointestinal Surgery*, **2007** , 11, 578-88	3.3	14
175	A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. *British Journal of Cancer*, **2007**, 96, 1358-67	8.7	10
174	Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*, **2007**, 110, 695-708	2.2	313
173	Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. *Cancer Research*, **2007**, 67, 3545-50	10.1	136
172	Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?. *Gut*, **2007**, 56, 1086-90	19.2	208
171	Effect of urban traffic, individual habits, and genetic polymorphisms on background urinary 1-hydroxypyrene excretion. *Annals of Epidemiology*, **2007**, 17, 1-8	6.4	23
170	Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation. *Journal of Molecular Diagnostics*, **2007**, 9, 151-7	5.1	13
169	Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. *Journal of Rheumatology*, **2007**, 34, 997-1004	4.1	39

168	Increased stability of P21(WAF1/CIP1) mRNA is required for ROS/ERK-dependent pancreatic adenocarcinoma cell growth inhibition by pyrrolidine dithiocarbamate. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2006**, 1763, 917-26	4.9	28
167	Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. *Surgery*, **2006**, 139, 347-56	3.6	109
166	SEL1L a multifaceted protein playing a role in tumor progression. *Journal of Cellular Physiology*, **2006**, 208, 23-38	7	34
165	Gastrinoma (duodenal and pancreatic). *Neuroendocrinology*, **2006**, 84, 173-82	5.6	216
164	Well-differentiated gastric tumors/carcinomas. *Neuroendocrinology*, **2006**, 84, 158-64	5.6	113
163	Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). *Neuroendocrinology*, **2006**, 84, 165-72	5.6	56
162	Well-differentiated pancreatic nonfunctioning tumors/carcinoma. *Neuroendocrinology*, **2006**, 84, 196-211	5.6	206
161	Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). *Neuroendocrinology*, **2006**, 84, 212-5	5.6	86
160	MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. *Journal of Clinical Oncology*, **2006**, 24, 4677-84	2.2	658
159	Well-differentiated pancreatic tumor/carcinoma: insulinoma. *Neuroendocrinology*, **2006**, 84, 183-8	5.6	191
158	Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2006**, 291, L457-65	5.8	26
157	Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. *Endocrine-Related Cancer*, **2006**, 13, 1213-21	5.7	78
156	Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. *Journal of Immunology*, **2006**, 177, 3448-60	5.3	103
155	A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2257-61	11.5	4710
154	Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. *Lancet Oncology, The*, **2006**, 7, 27-38	21.7	322
153	Intraductal papillary mucinous neoplasms and chronic pancreatitis. *Pancreatology*, **2006**, 6, 626-34	3.8	40
152	Rare functioning pancreatic endocrine tumors. *Neuroendocrinology*, **2006**, 84, 189-95	5.6	104
151	Finding of conjunctival melanocytic pigmented lesions within pterygium. *Histopathology*, **2006**, 48, 387-93	3.3	18

150	Non-invasive cancer detection: strategies for the identification of novel cancer markers. *IUBMB Life*, **2006**, 58, 193-8	4.7	9
149	Molecular characterization of composite mantle cell and follicular lymphoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 448, 639-43	5.1	21
148	Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 448, 797-804	5.1	64
147	TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 449, 395-401	5.1	1185
146	Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker. *Journal of Cancer Research and Clinical Oncology*, **2006**, 132, 45-50	4.9	8
145	Family history of gastric cancer: a correlation between epidemiologic findings and clinical data. *Gastric Cancer*, **2006**, 9, 9-13	7.6	60
144	The Dual Endothelin Receptor Antagonist Bosentan Prevents the Acute Sickle Cell-Related Hypoxic Lung and Kidney Injury in Transgenic SAD Mice.. *Blood*, **2006**, 108, 687-687	2.2	4
143	Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. *Haematologica*, **2006**, 91, 40-7	6.6	22
142	HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. *Blood*, **2005**, 106, 59-66	2.2	189
141	Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. *Journal of Proteome Research*, **2005**, 4, 1909-16	5.6	23
140	Specialized DNA arrays for the differentiation of pancreatic tumors. *Clinical Cancer Research*, **2005**, 11, 8048-54	12.9	41
139	Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. *Oncogene*, **2005**, 24, 199-211	9.2	74
138	Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. *Modern Pathology*, **2005**, 18, 1448-53	9.8	21
137	Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors. *Cancer Genetics and Cytogenetics*, **2005**, 156, 23-30		23
136	Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. *Cancer*, **2005**, 103, 1154-64	6.4	44
135	Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2005**, 446, 239-45	5.1	17
134	A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2005**, 447, 969-77	5.1	14
133	Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. *FASEB Journal*, **2005**, 19, 1125-7	0.9	114

132	K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. *Modern Pathology*, **2004**, 17, 538-46	9.8	44
131	Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2004**, 1693, 167-76	4.9	59
130	A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2004**, 444, 269-77	5.1	8
129	Allelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11. *Journal of Cancer Research and Clinical Oncology*, **2004**, 130, 339-45	4.9	4
128	Identification of the regulatory proteins in human pancreatic cancers treated with Trichostatin A by 2D-PAGE maps and multivariate statistical analysis. *Analytical and Bioanalytical Chemistry*, **2004**, 379, 992-1003	4.4	28
127	Protective Effects of No-Albumin and Albumin on Lung Injury Induced by Hypoxia/Reoxygenation in a Mouse Model of Sickle Cell Disease.. *Blood*, **2004**, 104, 3580-3580	2.2	
126	PDE-4 Inhibitor Rolipram Prevents Hypoxia Induced Pulmonary Hypertension in Transgenic Sickle Cell Sad Mice.. *Blood*, **2004**, 104, 3577-3577	2.2	
125	Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. *Haematologica*, **2004**, 89, 1091-9	6.6	17
124	Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. *Blood*, **2003**, 102, 1087-96	2.2	65
123	Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2003**, 443, 175-83	5.1	44
122	Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. *Electrophoresis*, **2003**, 24, 1871-8	3.6	38
121	Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine. *Electrophoresis*, **2003**, 24, 4291-303	3.6	49
120	Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. *Molecular Carcinogenesis*, **2003**, 38, 59-69	5	80
119	Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response. *Immunology*, **2003**, 110, 474-81	7.8	7
118	SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. *Oncogene*, **2003**, 22, 6359-68	9.2	32
117	Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement. *Laboratory Investigation*, **2003**, 83, 1155-63	5.9	20
116	Genetic abnormalities in pancreatic cancer. *Molecular Cancer*, **2003**, 2, 7	42.1	56
115	Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. *American Journal of Pathology*, **2003**, 162, 1495-502	5.8	541

114	Detection of human papillomavirus DNA in pterygia from different geographical regions. *British Journal of Ophthalmology*, **2003**, 87, 864-6	5.5	37
113	Genetics of gastric cancer: clinical implications. *I Supplementi Di Tumori*, **2003**, 2, S10-3		
112	Expression profiling by DNA microarrays. *Pathologica*, **2003**, 95, 277-8	1.9	
111	Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. *Journal of Surgical Oncology*, **2002**, 81, 45-53; discussion 54	2.8	69
110	Sex chromosome anomalies in pancreatic endocrine tumors. *International Journal of Cancer*, **2002**, 98, 532-8	7.5	50
109	Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2002**, 440, 155-159	5.1	12
108	Expression profiling of microdissected pancreatic adenocarcinomas. *Oncogene*, **2002**, 21, 4587-94	9.2	192
107	Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2002**, 441, 19-24	5.1	11
106	Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. *Pancreas*, **2002**, 25, e21-9	2.6	15
105	Acinar cell cystadenoma of the pancreas: a new entity?. *American Journal of Surgical Pathology*, **2002**, 26, 698-704	6.7	88
104	Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer. *Cancer Letters*, **2002**, 183, 179-83	9.9	10
103	Gene Expression Profiling as a Tool for the Identification of Molecular Targets. *Tumori*, **2002**, 1, S17-S20	1.7	1
102	Clinical significance of mutator phenotype and chromosome 17p and 18q allelic loss in gastric cancer. *British Journal of Surgery*, **2001**, 88, 419-25	5.3	14
101	Successful xenografting of cryopreserved primary pancreatic cancers. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2001**, 438, 154-8	5.1	33
100	Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2001**, 439, 798-802	5.1	278
99	Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis. *International Journal of Cancer*, **2001**, 91, 340-4	7.5	35
98	Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. *International Journal of Cancer*, **2001**, 91, 350-358	7.5	3
97	Helix pomatia agglutinin lectin-binding oligosaccharides of aggressive breast cancer. *International Journal of Cancer*, **2001**, 95, 79-85	7.5	36

96	Alteration of chromosome arm 6p is characteristic of primary mediastinal B-cell lymphoma, as identified by genome-wide allelotyping. *Genes Chromosomes and Cancer*, **2001**, 31, 191-5	5	24
95	Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. *Genes Chromosomes and Cancer*, **2001**, 32, 177-81	5	77
94	Gene expression profiles of pancreatic cancer and stromal desmoplasia. *Oncogene*, **2001**, 20, 7437-46	9.2	175
93	Parvalbumin is constantly expressed in chromophobe renal carcinoma. *Modern Pathology*, **2001**, 14, 760-7	3.8	86
92	Genetic alterations in primary mediastinal B-cell lymphoma: an update. *Leukemia and Lymphoma*, **2001**, 41, 47-53	1.9	11
91	Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. *British Journal of Cancer*, **2001**, 84, 253-62	8.7	150
90	Surgical strategy in the treatment of gastrointestinal neuroendocrine tumours. *Annals of Oncology*, **2001**, 12 Suppl 2, S101-3	10.3	9
89	Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. *Expert Review of Molecular Diagnostics*, **2001**, 1, 323-33	3.8	36
88	Cloning and functional analysis of SEL1L promoter region, a pancreas-specific gene. *DNA and Cell Biology*, **2001**, 20, 1-9	3.6	13
87	Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q. *American Journal of Pathology*, **2001**, 158, 317-21	5.8	89
86	Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. *International Journal of Cancer*, **2001**, 91, 350-8	7.5	38
85	High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. *Cancer Research*, **2001**, 61, 285-92	10.1	107
84	Renal angiomyolipoma with epithelioid sarcomatous transformation and metastases: demonstration of the same genetic defects in the primary and metastatic lesions. *American Journal of Surgical Pathology*, **2000**, 24, 889-94	6.7	104
83	Alcohol, smoking and papillomavirus infection as risk factors for esophageal squamous-cell papilloma and esophageal squamous-cell carcinoma in Italy. *International Journal of Cancer*, **2000**, 86, 874-8	7.5	59
82	Two novel polymorphisms, c1086T>C and c1798C>T, in the MADH4/DPC4 gene. *Human Mutation*, **2000**, 15, 485-6	4.7	3
81	Allelotype of pancreatic acinar cell carcinoma. *International Journal of Cancer*, **2000**, 88, 772-7	7.5	54
80	Identification of a novel mutation (c279delC) and a polymorphism (c291C>G) in the von Hippel-Lindau gene in Italian patients. *Human Mutation*, **2000**, 15, 582	4.7	
79	A novel germline mutation, P48T, in the CDKN2A/p16 gene in a patient with pancreatic carcinoma. *Human Mutation*, **2000**, 16, 447-8	4.7	11

78	Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. *Genes Chromosomes and Cancer*, **2000**, 28, 294-9	5	25
77	Intraductal papillary mucinous tumors of the pancreas. Verona University Pancreatic Team. *International Journal of Gastrointestinal Cancer*, **2000**, 27, 181-93		22
76	Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. *Gut*, **2000**, 46, 842-8	19.2	34
75	Analysis of CIITA encoding AIR-1 gene promoters in insulin-dependent diabetes mellitus and rheumatoid arthritis patients from the northeast of Italy: absence of sequence variability. *Human Immunology*, **2000**, 61, 599-604	2.3	14
74	Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial in the north-east of Italy and evaluation of the diagnostic protocol's adequacy. *Recent Results in Cancer Research*, **2000**, 156, 116-24	1.5	41
73	Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. *British Journal of Haematology*, **1999**, 107, 106-13	4.5	36
72	Genomic anomalies in pancreatic tumors other than common adenocarcinoma. *Annals of the New York Academy of Sciences*, **1999**, 880, 179-90	6.5	1
71	Hepatitis C virus infection of peripheral nerves in type II cryoglobulinaemia. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **1999**, 434, 533-5	5.1	51
70	Intermediate results of extended pancreaticoduodenectomy. Verona experience. *Journal of Hepato-Biliary-Pancreatic Surgery*, **1999**, 6, 74-8		6
69	Nonrandom chromosomal imbalances in primary mediastinal b-cell lymphoma detected by arbitrarily primed PCR fingerprinting **1999**, 26, 203-209		29
68	Correlation of poly(ADP-ribose)polymerase and p53 expression levels in high-grade lymphomas. *Molecular Carcinogenesis*, **1999**, 25, 256-61	5	17
67	Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. *American Journal of Surgical Pathology*, **1999**, 23, 410-22	6.7	560
66	The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. *Cancer Research*, **1999**, 59, 1308-14	10.1	43
65	Nonrandom chromosomal imbalances in primary mediastinal B-cell lymphoma detected by arbitrarily primed PCR fingerprinting. *Genes Chromosomes and Cancer*, **1999**, 26, 203-9	5	0
64	Molecular pathogenesis of sporadic duodenal cancer. *British Journal of Cancer*, **1998**, 77, 760-5	8.7	29
63	Chromosome 5 allelic losses are early events in tumours of the papilla of Vater and occur at sites similar to those of gastric cancer. *British Journal of Cancer*, **1998**, 78, 1653-60	8.7	41
62	Pancreatic carcinoma **1998**, 82, 1649-1656		31
61	Clonality of B-cells in portal lymphoid infiltrates of HCV-infected livers. *Journal of Pathology*, **1998**, 185, 86-90	9.4	40

60	Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. *Journal of Pathology*, **1998**, 186, 41-50	9.4	57
59	Molecular approach in human tumor investigation: oncogenes, tumor suppressor genes and DNA tumor polyomaviruses (review). *International Journal of Molecular Medicine*, **1998**, 1, 1011-23	4.4	
58	Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. *Italian Journal of Gastroenterology and Hepatology*, **1998**, 30, 414-7		17
57	Molecular techniques in hematopathology. *Leukemia and Lymphoma*, **1997**, 26 Suppl 1, 77-82	1.9	3
56	The human ALL-1/MLL/HRX antigen is predominantly localized in the nucleus of resting and proliferating peripheral blood mononuclear cells. *Cancer Research*, **1997**, 57, 2035-41	10.1	17
55	Cancers of the papilla of vater: mutator phenotype is associated with good prognosis. *Clinical Cancer Research*, **1997**, 3, 1841-7	12.9	34
54	p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. *Blood*, **1996**, 88, 4012-4020	2.2	59
53	Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. *Tissue Antigens*, **1996** , 48, 301-11		41
52	APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis. *International Journal of Cancer*, **1996**, 68, 305-12	7.5	44
51	Carcinoma-like signet-ring cells in gastric mucosa-associated lymphoid tissue (MALT) lymphoma. *American Journal of Surgical Pathology*, **1996**, 20, 588-98	6.7	34
50	Chromosome 7q allelic losses in pancreatic carcinoma. *Cancer Research*, **1996**, 56, 3808-13	10.1	75
49	p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. *Blood*, **1996**, 88, 4012-20	2.2	14
48	Routine application of polymerase chain reaction in the diagnosis of monoclonality of B-cell lymphoid proliferations. *Diagnostic Molecular Pathology*, **1995**, 4, 14-24		101
47	Nodular lymphocyte predominant Hodgkin's disease and anaplastic large-cell (CD30+) lymphoma: distinct entities or nonspecific patterns?. *Seminars in Diagnostic Pathology*, **1995**, 12, 256-69	4.3	6
46	Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. *Blood*, **1994**, 84, 4295-4300	2.2	37
45	Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **1994**, 425, 357-67	5.1	269
44	Common acute lymphoblastic leukaemia-lymphoma expressing cytokeratin: a case report. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **1994**, 425, 83-7	5.1	7
43	Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. *International Journal of Cancer*, **1994**, 57, 167-71	7.5	70

42	ras-family gene mutations in neoplasia of the ampulla of Vater. *International Journal of Cancer*, **1994**, 59, 39-42	7.5	52
41	Immunohistochemical distribution of endothelin in biopsies of pediatric nephrotic syndrome. *American Journal of Nephrology*, **1994**, 14, 157-61	4.6	19
40	Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. *Blood*, **1994**, 84, 4295-300	2.2	7
39	A CD5+ leukemic lymphoma with monocytoid features: an unusual B-cell lymphoma mimicking hairy-cell leukemia. *Acta Haematologica*, **1993**, 89, 94-9	2.7	10
38	Subtypes of Epstein-Barr virus in HIV-1-associated and HIV-1-unrelated Hodgkin's disease cases. *International Journal of Cancer*, **1993**, 54, 895-8	7.5	19
37	Expression of progesterone receptors in solid-cystic tumour of the pancreas: a clinicopathological and immunohistochemical study of ten cases. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1993**, 423, 425-31		73
36	Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. *American Journal of Pathology*, **1993**, 142, 1163-72	5.8	81
35	Pancreatic adenocarcinomas frequently show p53 gene mutations. *American Journal of Pathology*, **1993**, 142, 1534-43	5.8	225
34	Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. *American Journal of Pathology*, **1993**, 143, 1348-55	5.8	39
33	Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. *American Journal of Surgical Pathology*, **1992**, 16, 1215-23	6.7	71
32	Neoplastic epithelial cells in a subset of human thymomas express the B cell-associated CD20 antigen. *American Journal of Surgical Pathology*, **1992**, 16, 988-97	6.7	36
31	Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes. *Annals of Oncology*, **1992**, 3, 307-10	10.3	19
30	Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. *Cancer Research*, **1992**, 52, 3674-8	10.1	107
29	p53 gene mutation spectrum in hepatocellular carcinoma. *Cancer Research*, **1992**, 52, 6358-64	10.1	169
28	False-positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimelanoma monoclonal antibody HMB45. *American Journal of Clinical Pathology*, **1991**, 95, 454-9	1.9	54
27	Evidence of c-myc gene abnormalities in mediastinal large B-cell lymphoma of young adult age [see comments]. *Blood*, **1991**, 78, 780-788	2.2	50
26	Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. *Hematologic Pathology*, **1991**, 5, 67-73		23
25	Evidence of c-myc gene abnormalities in mediastinal large B-cell lymphoma of young adult age. *Blood*, **1991**, 78, 780-8	2.2	5

24	Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. *Pathology*, **1991**, 23, 185-8	1.6	185
23	Expression and gene rearrangement of the T-cell receptor in human thymomas. *Vigiliae Christianae*, **1990**, 58, 235-9	0.2	3
22	Small-cell neuroendocrine carcinoma of the ampullary region. A clinicopathologic, immunohistochemical, and ultrastructural study of three cases. *American Journal of Surgical Pathology*, **1990**, 14, 703-13	6.7	57
21	Peripheral giant cell granuloma: evidence for osteoclastic differentiation. *Oral Surgery, Oral Medicine, and Oral Pathology*, **1990**, 70, 471-5		39
20	Prevalence of human papillomaviruses in cervical scrapings of unselected women. *European Journal of Clinical Microbiology and Infectious Diseases*, **1990**, 9, 703-4	5.3	0
19	A method for detection of human papillomavirus DNA in stored slides of stained cervical smears. *Pathology Research and Practice*, **1990**, 186, 666-7	3.4	
18	Isolation of multicellular complexes of follicular dendritic cells and lymphocytes: immunophenotypical characterization, electron microscopy and culture studies. *Cell and Tissue Research*, **1989**, 257, 9-15	4.2	13
17	T-cell-rich B-cell lymphoma. *American Journal of Surgical Pathology*, **1989**, 13, 335-7	6.7	27
16	Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumours. An immunohistochemical study on paraffin sections. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1988**, 413, 17-24		78
15	Analysis of the methylation pattern of c-Ha-ras oncogene in human prostatic cancer. *Italian Journal of Biochemistry*, **1988**, 37, 104-10		
14	Mediastinal large-cell lymphoma with sclerosis. Genotypic analysis establishes its B nature. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1987**, 412, 17-21		41
13	Immunohistological analysis of Rosai-Dorfman histiocytosis. A disease of S-100 + CD1-histiocytes. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1987**, 411, 129-35		55
12	Hyaline-vascular type of Castleman's disease (angiofollicular lymph node hyperplasia) with monotypic plasma cells. An immunohistochemical study with monoclonal antibodies. *Histology and Histopathology*, **1987**, 2, 49-55	1.4	6
11	Immunohistochemical evidence of active thymocyte proliferation in thymoma. Its possible role in the pathogenesis of autoimmune diseases. *American Journal of Pathology*, **1987**, 128, 464-70	5.8	25
10	Mediastinal large-cell lymphoma of B-type, with sclerosis: histopathological and immunohistochemical study of eight cases. *Histopathology*, **1986**, 10, 589-600	7.3	87
9	Blastic OKT6-positive proliferation preceding malignant histiocytosis. *Histology and Histopathology*, **1986**, 1, 391-7	1.4	2
8	Hyperplastic (metaplastic) polyps of the colon. A histologic and histochemical study. *American Journal of Surgical Pathology*, **1984**, 8, 687-98	6.7	54
7	Mucin secretion and morphological changes of the mucosa in non-neoplastic diseases of the colon. *Histopathology*, **1983**, 7, 707-18	7.3	41

6	Juvenile and inflammatory polyps of the colon--a histological and histochemical study. *Histopathology*, **1983**, 7, 719-28	7.3	19
5	"The evolution of the solitary ulcer of the rectum"--an endoscopic and histopathological study. *Endoscopy*, **1982**, 14, 131-4	3.4	15
4	Transitional polyps of the colon. *Endoscopy*, **1982**, 14, 174-5	3.4	6
3	"Transitional" and hyperplastic-metaplastic mucosa occurring in solitary ulcer of the rectum. *Histopathology*, **1981**, 5, 527-33	7.3	35
2	Revealing unidentified heterogeneity in different epithelial cancers using heterocellular subtype classification		2
1	Integrating supportive care into the multidisciplinary management of lung cancer: we can wait any longer. *Expert Review of Anticancer Therapy*,1-11	3.5	0